Sameem Abedin, MD | Froedtert & the ...

Dr. Sameem M. Abedin

Claim this profile

Medical College of Wisconsin

Studies Acute Myelogenous Leukemia
Studies Acute Myeloid Leukemia
14 reported clinical trials
33 drugs studied

Area of expertise

1Acute Myelogenous Leukemia
Sameem M. Abedin has run 8 trials for Acute Myelogenous Leukemia. Some of their research focus areas include:
FLT3 positive
D835 positive
RUNX1-RUNX1T1 negative
2Acute Myeloid Leukemia
Sameem M. Abedin has run 8 trials for Acute Myeloid Leukemia. Some of their research focus areas include:
FLT3 positive
D835 positive
RUNX1-RUNX1T1 negative

Affiliated Hospitals

Image of trial facility.
Medical College Of Wisconsin
Image of trial facility.
The Medical College Of Wisconsin

Clinical Trials Sameem M. Abedin is currently running

Image of trial facility.

Venetoclax + HMA

for Acute Myeloid Leukemia

This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed into DNA and leads to the activation of cancer suppressor genes, which are genes that help control cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gilteritinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply. This study may help doctors find out if these different approaches are better than the usual approaches. To decide if they are better, the study doctors are looking to see if the study drugs lead to a higher percentage of patients achieving a deeper remission compared to the usual approach.
Recruiting1 award Phase 27 criteria
Image of trial facility.

Venetoclax, Azacitidine, and Cusatuzumab

for Acute Myeloid Leukemia

The goal of this clinical trial is to learn if participants treated with the experimental drug cusatuzumab added to venetoclax and azacitidine works to treat acute myeloid leukemia (AML) compared to venetoclax and azacitidine. Venetoclax and azacitidine are drugs commonly used to treat AML in patients that are unable to receive chemotherapy to treat AML. The main question the clinical trial aims to answer is does cusatuzumab added to venetoclax and azacitidine prolong the length of time participants live compared to venetoclax and azacitidine?
Recruiting1 award Phase 21 criteria

More about Sameem M. Abedin

Clinical Trial Related6 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Sameem M. Abedin has experience with
  • Cyclophosphamide
  • Ruxolitinib
  • Venetoclax
  • Gilteritinib
  • Neihulizumab
  • Cytarabine

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Sameem M. Abedin specialize in?
Is Sameem M. Abedin currently recruiting for clinical trials?
Are there any treatments that Sameem M. Abedin has studied deeply?
What is the best way to schedule an appointment with Sameem M. Abedin?
What is the office address of Sameem M. Abedin?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security